Using available clinical trial data for ER + /HER2- BC patients with known clinical outcomes following palbociclib treatment (NeoPalAna) [28], we found that low expression of the top two validated genes, SLC40A1 and TGFB3, correlated with resistance to palbociclib. This evidence concerns the gene TGFB3 and breast cancer.